Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621) - Fox, Elizabeth; Mosse', Yael P.; Meany, Holly M.; Gurney, James G.; Khanna, Geetika; Jackson, Hollie A.; Gordon, Gary; Shusterman, Suzanne; Park, Julie R.; Cohn, Susan L.; Adamson, Peter C.; London, Wendy B.; et al. (Pediatric blood & cancer, 2014)
Keywords: Adolescent; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Biomarkers; Capsules; Child; Child, Preschool; childhood cancer; clinical trial; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Diseases - chemically induced; Hematologic Diseases - chemically induced; Hematology; Humans; Male; microtubule inhibitor; Nervous System Diseases - chemically induced; neuroblastoma; Neuroblastoma - drug therapy; Neuroblastoma - therapy; Oncology; Pediatrics; Quality of Life; Recurrence; Salvage Therapy; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Sulfonamides - therapeutic use; Suspensions; time to progression; Treatment Failure; Tubulin Modulators - therapeutic use; clinical trial; neuroblastoma; childhood cancer; time to progression; microtubule inhibitor